VIV:TSX.V; VIVXF:OTCQB

Avivagen Inc.

Avivagen is developing and commercializing products that promote health in animals and humans. The Corporation’s unique OxC-beta™ technology is a proprietary, first-in-class source of β-carotene-oxygen copolymer compounds that confer a variety of non-vitamin A health benefits. These benefits have wide, global utility, including replacement of antibiotics in livestock feeds, as well as for food-production conditions where antibiotics cannot be used, and supporting good health in companion animals.
VIV:TSX.V VIVXF:OTCQB

Expert Comments:

This agreement will provide another sales channel and additional revenue opportunities for Avivagen's proprietary product.
read more >

Clive Maund, CliveMaund.com

(1/31/20)
"Given the huge strides that Avivagen Inc. is making towards its objectives, it is truly astounding that its stock hasn't taken off higher already, especially given that it still has a relatively modest number of shares in issue. . .it looks like it could very soon. . .the company looks like a most attractive stock here, so we stay long and it is rated an immediate Strong Buy."

The company makes progress getting its products approved and sold in more countries.
read more >
The product contains the firm's OxC-beta™ supplement.
read more >
This is a significant achievement of this developing company.
read more >

David Bautz, Zacks Small-Cap Research

(1/10/20)
"Avivagen Inc. entered into an agreement with COFCO Biotechnology Co. Ltd. in which COFCO will assist the company in securing regulatory approval for OxC-beta Livestock in China. . .we believe it is a great partner to assist Avivagen. . .China represents a tremendous opportunity for it as the Chinese government has announced a plan to ban all antibiotics in livestock feed by July 2020." — -Zacks Small-Cap Research

The requirements include, among others, trials of the company's livestock feed additive.
read more >
This is the first step toward a binding, definitive agreement between the two companies.
read more >
The maiden order comes on the heels of the country approving use of the product there.
read more >
Now, the company has the green light to sell this product in eight countries.
read more >

David Bautz, Zacks Small-Cap Research

(11/19/19)
"We are initiating coverage of Avivagen Inc. with a $2.50 valuation. The company is developing products to support animal health, which includes replacing antibiotics in livestock feeds with proprietary compounds that promote the growth and overall health of the animal through support of the host's innate immune system." -Zacks Small-Cap Research

With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth.
read more >
Technical analyst Clive Maund believes this stock could gain traction soon.
read more >
The developer received an initial order from Taiwan for the product.
read more >
Demand for the Canadian company's product is growing in the Asia-Pacific region.
read more >

Clive Maund, CliveMaund.com

(5/11/19)
"This looks like an excellent point to buy back Avivagen Inc. . .the price is believed to be completing an intermediate base after correcting back to support. Volume indications are very favorable. . .rated an Immediate Strong Buy."

More Expert Comments

Experts Following This Company

Clive Maund – CliveMaund.com
headshot of Steve Palmer
Steve Palmer, President and Chief Investment Officer – AlphaNorth Asset Management

The information provided above is from analysts, newsletters, the company and other contributors.

Avivagen Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Effective natural substitute for antibiotics in animal feed
 
Six families of patents extending beyond 2035
 
Antibiotic ban in animal feed being led by Governments
catalyst Calendar
Q1
2019
Nutraceutical deal/JV
Q3
2019
GRAS approval for livestock in the USA
Q4
2019
Chinese approval for livestock